logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12496282 B1

PDFFull Text
Date of Patent:
Dec. 16, 2025

Filed:

May. 10, 2024

Hepatitis b antiviral agents

Applicant:

Enanta Pharmaceuticals, Inc., Watertown, MA (US);

Inventors:

Yao-Ling Qiu, Andover, MA (US);

Xuri Gao, Newtonville, MA (US);

Jorden Kass, Arlington, MA (US);

Hui Cao, Belmont, MA (US);

Wei Li, Lexington, MA (US);

Xiaowen Peng, Sudbury, MA (US);

Byung-Chul Suh, Lexington, MA (US);

Yat Sun Or, Waltham, MA (US);

Assignee:

Enanta Pharmaceuticals, Inc., Watertown, MA (US);

Attorneys:

Edgar W. Harlan

Carolyn S. Elmore

Elmore Patent Law Group, P.C.

Primary Examiner:

Pancham Bakshi

Int. Cl.
CPC ...
A61K 31/167 (2006.01); A61K 31/337 (2006.01); A61K 31/34 (2006.01); A61K 31/351 (2006.01); A61K 31/357 (2006.01); A61K 31/397 (2006.01); A61K 31/401 (2006.01); A61K 31/4015 (2006.01); A61K 31/415 (2006.01); A61K 31/4164 (2006.01); A61K 31/4192 (2006.01); A61K 31/421 (2006.01); A61K 31/426 (2006.01); A61K 31/4409 (2006.01); A61K 31/4439 (2006.01); A61K 31/47 (2006.01); A61K 31/513 (2006.01); A61K 31/7028 (2006.01); A61P 31/20 (2006.01); C07C 303/00 (2006.01); C07C 317/44 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/167 (2013.01); A61K 31/337 (2013.01); A61K 31/34 (2013.01); A61K 31/351 (2013.01); A61K 31/357 (2013.01); A61K 31/397 (2013.01); A61K 31/401 (2013.01); A61K 31/4015 (2013.01); A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/4192 (2013.01); A61K 31/421 (2013.01); A61K 31/426 (2013.01); A61K 31/4409 (2013.01); A61K 31/4439 (2013.01); A61K 31/47 (2013.01); A61K 31/513 (2013.01); A61K 31/7028 (2013.01); A61P 31/20 (2018.01); C07C 303/00 (2013.01); C07C 317/44 (2013.01); A61K 45/06 (2013.01); C07B 2200/05 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/10 (2017.05); C07C 2601/14 (2017.05); C07C 2601/16 (2017.05); C07C 2602/44 (2017.05); C07C 2602/50 (2017.05);
Abstract

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:X-A-Y-L-R  (I)which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Find Patent Forward Citations

Loading…